These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 29650143)

  • 1. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
    Todenhöfer T; Boegemann M
    Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immunotherapy in bladder cancer.
    Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
    Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
    Szarvas T; Oláh C; Riesz P; Géczi L; Nyirády P
    Orv Hetil; 2019 Oct; 160(42):1647-1654. PubMed ID: 31608691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.